These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11598535)

  • 1. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
    Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
    Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
    Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
    Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
    Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
    Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
    François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
    Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
    Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
    Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G
    J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
    Sculpher M; Palmer MK; Heyes A
    Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
    Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltitrexed in colorectal cancer.
    Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
    Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
    Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.